33042-66-9

Basic information

• Product Name: SPIRO[INDENE-1,4'-PIPERIDINE]
• Synonyms: SPIRO[INDENE-1,4'-PIPERIDINE];Spiro[1H-indene-1,4'-piperidine];EOS-62210
• CAS NO: 33042-66-9
• Molecular Formula: C₁₃H₁₅N
• Molecular Weight: 185.2649
• Mol File: 33042-66-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 318.721 °C at 760 mmHg
• Flash Point: 155.442 °C
• Appearance: /
• Density: 1.099 g/cm³
• Storage Temp.: 2-8°C(protect from light)
• PKA: 10.70±0.20(Predicted)
• CAS DataBase Reference: SPIRO[INDENE-1,4'-PIPERIDINE](CAS DataBase Reference)
• NIST Chemistry Reference: SPIRO[INDENE-1,4'-PIPERIDINE](33042-66-9)
• EPA Substance Registry System: SPIRO[INDENE-1,4'-PIPERIDINE](33042-66-9)

Safety Data

• Hazardous Substances Data: 33042-66-9(Hazardous Substances Data)

Usage

General Description

SPIRO[INDENE-1,4'-PIPERIDINE] is a chemical compound with a unique and complex molecular structure. It contains a spiro ring system with an indene and piperidine ring fused together, resulting in a tertiary amine functionality. This chemical has potential applications in the field of medicinal chemistry and drug discovery, particularly in the development of novel pharmaceuticals. The spirocyclic nature of this compound, along with its conformational flexibility and distinct stereochemistry, make it a valuable scaffold for the design of biologically active molecules. Researchers are exploring the synthesis and properties of SPIRO[INDENE-1,4'-PIPERIDINE] to uncover its potential as a versatile building block in organic synthesis and drug development.

Upstream product

• 95-13-6 1-indene 
• 137419-24-0 1'-(tert-butyloxycarbonyl)spiro<1H-indene-1,4'-piperidine> 

Downstream Products

• 691875-95-3 C₂₉H₃₆N₂O₄ 
• 691875-98-6 C₂₄H₂₆BrNO₂ 
• 1292291-71-4 Ethyl 3-[2-fluoro-4-[[3-methoxy-4-(spiro[indene-1,4'-piperidine]-1'-ylmethyl)phenyl]methoxy]phenyl]propanoate 
• 1416435-96-5 5-isoxazoyl-Cha-Ile-spiro[1H-indene-1,4'-piperidine] 
• 1309435-60-6 (3S)-3-[4-[[5-(spiro[indene-1,4'-piperidine]-1'-ylmethyl)-2-thienyl]methoxy]phenyl]hex-4-ynoic acid 
• 1309436-19-8 ethyl (3S)-3-[4-[[5-(spiro[indene-1,4'-piperidine]-1'-ylmethyl)-2-thienyl]methoxy]phenyl]hex-4-ynoate 
• 1204429-71-9 1-[spiro(indene-1,4'-piperidine)-1'-yl]-2-[2-(trifluoromethyl)phenoxy]ethanone 
• 208706-12-1 C₃₃H₄₁N₅O₂ 

Relevant articles and documents

A class of GPR40 agonist compounds with amide structure, and uses thereof

The present invention relates to a class of amide compounds with a novel structure, and a pharmaceutical composition thereof, wherein the structure of the amide compound is represented by a general formula (I). According to the present invention, the amide compound (I) can regulate GPR40 activity, and can be used for GPR40 activity related diseases such as diabetes and metabolic syndrome. The formula I is defined in the specification.

SUBSTITUTED HETEROCYCLIC DERIVATIVES AS GPR AGONISTS AND USES THEREOF

The present invention generally relates to substituted heterocyclic derivatives (the compounds of Formula (I)), processes for their preparation, pharmaceutical compositions containing said compounds, their use as G-protein coupled receptor (GPR) agonists, particularly as GPR40 agonists and methods of using these compounds in the treatment of GPR40 mediated diseases or conditions such as Type 2 diabetes, obesity, dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS

The invention relates to indol-3-yl-carbonyl-spiro-piperidine derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the spiro-piperidine head group A and the residues R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, methods for preparing the compounds and pharmaceutical compositions, and their use in the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.